Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06525740 · ClinicalTrials.gov registry record · Phase 4
Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery
A Phase 4 study of Malignant Female Reproductive System Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT06525740: Recruiting Phase 4 study of Malignant Female Reproductive System Neoplasm, sponsored by Mayo Clinic.
NCT06525740 is a Phase 4 study of Malignant Female Reproductive System Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 140 participants, below the 397-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06525740, a Phase 4 study of Malignant Female Reproductive System Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase IV trial compares methadone versus hydromorphone given in the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord (intrathecal) for postoperative pain relief in patients with gynecologic cancer undergo surgery. Methadone binds to opioid receptors in the central nervous system and is a long-acting opioid pain medication. Intrathecal hydromorphone works by changing the way the brain and nervous system respond to pain and is similar to an epidural. This trial may help researchers determine if methadone works as well as intrathecal hydromorphone for pain relief after surgery in patients with gynecologic cancer.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Methadone
- DRUG Hydromorphone
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06525740
The ClinicalTrials.gov registry entry for NCT06525740 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 397-participant average among 18 other Malignant Female Reproductive System Neoplasm trials with a reported enrollment target (65% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Female Reproductive System Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT06525740 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06525740 about?
NCT06525740 is a clinical study titled "Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery". This phase IV trial compares methadone versus hydromorphone given in the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord (intrathecal) for postoperative pain relief in patients with gynecologic cancer undergo surgery. Methadone binds to opioid receptors in t...
What is the current status of trial NCT06525740?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2024-09-03. Estimated completion is 2029-09-01.
What conditions does trial NCT06525740 study?
This clinical trial studies the following conditions: Malignant Female Reproductive System Neoplasm.
What interventions are being tested in trial NCT06525740?
The interventions under investigation include: Questionnaire Administration (OTHER), Methadone (DRUG), Hydromorphone (DRUG).
Who is sponsoring clinical trial NCT06525740?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06525740 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Female Reproductive System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors
RECRUITING · NA
-
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
RECRUITING
-
Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer
RECRUITING · Phase 2
-
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
RECRUITING · Phase 3
-
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
RECRUITING
-
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.